Papers/PMID:33671220
Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial.
Nutrients2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid — decreases necrotising enterocolitis incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Confirmed NEC was lower in infants from the DHA-group compared with the control-group (0/100 vs. 7/100, p = 0.007) with a RR of 0.93 (95% CI 0.881 to 0.981, p = 0.008); there was a risk difference of −7% (95% CI −12.00 to −1.99), and a number needed to treat of 15 (95% CI 8.3 to 50).”
Quoted verbatim from Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial.. - Study
- RCT
- Duration
- 14 days
- Dose
- 75 mg DHA/kg body weight daily for 14 days from the first enteral feed
- Population
- Preterm infants (birthweight 1000-1500 g) dosed enterally by orogastric tube; outcome measured in the same infants; per-protocol analysis; confirmed NEC defined as Bell stage IIa or greater (modified Walsh)
Effect 0.93 risk ratio, 95% CI 0.881 to 0.981
Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial.2021PMID:33671220An author is affiliated with a producerPermalink